Hepatocellular carcinoma

Dr. LIANG Xiao of SRRSH Invited as ELSA 2023 Sole Keynote Speaker from Mainland China

Retrieved on: 
Wednesday, October 11, 2023
Congress, General surgery, CAI, Health care, Medicine, Cai, Endoscopy, Sir Run Run Shaw Hospital, University of the Chinese Academy of Sciences, Government, Hepatocellular carcinoma, Zhejiang University School of Medicine, The Hospital, Robotics, Hospital, Chinese Academy of Medical Sciences COVID-19 vaccine, Trauma, Speech, Assistant, SRRSH, Minimally invasive procedure, China Association for Science and Technology, Research, Science, Medical device, Dentistry

Dr. LIANG Xiao delivered a speech titled "New Era of Minimally Invasive Surgery for Hepatocellular Carcinoma in China", sharing the latest and significant technological advancements in minimally invasive surgery with the audience.

Key Points: 
  • Dr. LIANG Xiao delivered a speech titled "New Era of Minimally Invasive Surgery for Hepatocellular Carcinoma in China", sharing the latest and significant technological advancements in minimally invasive surgery with the audience.
  • With great enthusiasm, Dr. LIANG introduced SRRSH, which is dedicated to promoting and applying minimally invasive surgical techniques.
  • The Hospital is one of the leading institutions in China with the broadest range of minimally invasive surgical procedures and involvement in various disciplines.
  • With Dr. CAI Xiujun, the President of SRRSH, leading the way, the Hospital has progressed steadily, achieving remarkable results.

Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

Retrieved on: 
Monday, October 16, 2023
Other Health, Health, Genetics, Health Technology, Oncology, Congress, DFS, Neoplasm, Doctor of Philosophy, Hepatocellular carcinoma, NTRA, Nature Medicine, Abstract, LARC, Master of Science, RCC, DNA, Survival, CRC, Cancer, Recurrence, Disease, Renal cell carcinoma, Colorectal cancer, European Society for Medical Oncology, ESMO, AA, Pan-cancer analysis, ECD, MRD, Cohort (statistics), HCC, Patient, BTC, Pharmaceutical industry, Medical imaging, Aroma compound, MD, Natera

Natera and its collaborators will present MRD data in a total of seven abstracts, including a mini-oral and several poster presentations.

Key Points: 
  • Natera and its collaborators will present MRD data in a total of seven abstracts, including a mini-oral and several poster presentations.
  • Other presentations will highlight new Signatera data in rectal cancer, appendiceal adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, and other solid tumors.
  • “We look forward to the presentation of updated data from the landmark CIRCULATE-Japan study.
  • Presentation #1908P | Renal Cancer | Oct. 23 | Presenter: Michael Smigelski, MD
    This study demonstrates that longitudinal ctDNA monitoring may be predictive of recurrence-free survival post-surgery in patients with RCC.

OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors

Retrieved on: 
Monday, October 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Ligand, Tumor microenvironment, Mnemos EP, Hepatocellular carcinoma, AACR, PD-L1, Communication, MTD, Preventive healthcare, Index, OSE, PD-L2, ISIN, Maxima and minima, Conference, Patient, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).
  • Silvia Comis, Head of Clinical Development and Regulatory Affairs of OSE Immunotherapeutics, comments: “These first efficacy and safety positive results from clinical Phase 1/2 assessing the therapeutic potential of our proprietary anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors are very promising.
  • These results encourage further clinical development of OSE-279 in the future as a monotherapy treatment in pre-identified cancer niche indications, with still high unmet medical needs.
  • This product will also be available for combination with other OSE drug candidates or with external assets opening new potential partnerships.”
    The communication reported on the first positive results from the Phase 1/2 clinical trial evaluating OSE-279 monotherapy in patients with advanced solid tumors, with no therapeutic option available.

CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation

Retrieved on: 
Sunday, October 15, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Congress, Phagocytosis, Tumor microenvironment, Hepatocellular carcinoma, NSCLC, Safety, Lung cancer, Interim, Grenfell Tower Inquiry Phase 2, Cancer, ESMO, MHC-II, Nivolumab, Nature Communications, Bladder cancer, European Society for Medical Oncology, ASCO, Neoplasm, Macrophage, Cytokine, Antigen, Chemokine, HCC, Patient, Oxidative stress, Vaccine

CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance.

Key Points: 
  • CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance.
  • The data are the first to show that GDF-15 has an inhibitory effect on the activation of M1 macrophages.
  • These specific myeloid lineage immune cells are central to the initiation of immune responses, including the secretion of pro-inflammatory cytokines and chemokines, presentation of antigens as well as direct antitumor cytotoxicity.
  • Overall, the results indicate that GDF-15 counteracts myeloid immune cell activation, supporting the generation of an immune-evasive tumor microenvironment, an important feature in therapy resistance.

Bayer Unveils Latest Data from Oncology Portfolio at ESMO Congress 2023

Retrieved on: 
Thursday, October 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Congress, Disease, Trifluridine/tipiracil, Hepatocellular carcinoma, NSCLC, PLT, ORR, Bevacizumab, Observational study, Liver transplantation, Safety, Lung cancer, Mutation, RAS, Metastasis, Cancer, NTRK, European Society for Medical Oncology, ESMO, FDA, Prostate-specific antigen, Docetaxel, Quality of life (healthcare), Radium, Phase, REG, BAY, ADT, Patient, PSA, CNS, HCC, TRK, Radium-223, TKI, Pharmaceutical industry, Bayer

Bayer will present new data from across its oncology portfolio at the upcoming European Society for Medical Oncology (ESMO) Congress taking place in Madrid, Spain from October 20-24, 2023.

Key Points: 
  • Bayer will present new data from across its oncology portfolio at the upcoming European Society for Medical Oncology (ESMO) Congress taking place in Madrid, Spain from October 20-24, 2023.
  • The breadth of new data showcases Bayer’s ongoing commitment to supporting patients living with cancer.
  • In addition, Bayer will present new data on health-related quality of life (HRQoL) deterioration-free survival (DetFS) by PSA decline in the Phase III ARAMIS trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
  • Details on presentations from Bayer for the 2023 ESMO Congress are listed below:
    Regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world (RW) practice: Final analysis of the prospective, observational REFINE study by prior liver transplantation (PLT)

FDA Awards HistoSonics Clearance of its First-of-a-Kind Edison® Histotripsy System

Retrieved on: 
Monday, October 9, 2023
Surgery, Medical Devices, FDA, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Oncology, Congress, Infection, Food, Hepatocellular carcinoma, Blue, Breast, Rectum, Liver disease, Liver, Radiation, Safety, University, CTCAE, Patient, Education, High-intensity focused ultrasound, Thomas Edison, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Amaral, Colon, Science, Neoplasm, Needle, HCC, Physician, Medical imaging

Marketing authorization makes Edison the first and only histotripsy platform available in the Unites States.

Key Points: 
  • Marketing authorization makes Edison the first and only histotripsy platform available in the Unites States.
  • View the full release here: https://www.businesswire.com/news/home/20231009669222/en/
    HistoSonics Edison Histotripsy System (Photo: Business Wire)
    FDA authorization was based, in part, on data from the #HOPE4LIVER Trials in 13 trial sites across the US and Europe.
  • HistoSonics' Edison System uses proprietary technology and advanced imaging to deliver personalized, non-invasive histotripsy treatments with precision and control.
  • The Edison System is indicated for the non-invasive destruction of liver tumors, including unresectable liver tumors, using a non-thermal, mechanical process of focused ultrasound.

Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 4, 2023
MYC, Human, Hepatocellular carcinoma, NSCLC, Lung cancer, Messenger, Cancer, Poster, Therapy, Conference, Dietary supplement

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data supporting the potential of OTX-2101, a c-MYC (MYC)-targeting epigenomic controller being developed for the treatment of non-small cell lung cancer (NSCLC), at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts, October 11 – 15, 2023.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data supporting the potential of OTX-2101, a c-MYC (MYC)-targeting epigenomic controller being developed for the treatment of non-small cell lung cancer (NSCLC), at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts, October 11 – 15, 2023.
  • “We are excited to present new preclinical data from our NSCLC program that build on our recent preliminary clinical results in hepatocellular carcinoma, which demonstrated for the first time our ability to modulate MYC expression pre-transcriptionally in humans using a programmable mRNA development candidate,” said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics.
  • “These new data highlight the broad applicability of our MYC-targeting strategy across solid tumors and its potential to synergize with clinically validated therapeutic options.
  • We look forward to advancing our preclinical and clinical studies to address MYC-driven cancers.”
    Details for the poster presentation are as follows:
    The poster will be made available on the Omega website at https://omegatherapeutics.com/our-science/#publications-research at the same time as the presentation.

New Physician Guidelines Recommend Contrast Enhanced Ultrasound to Diagnose Certain Liver Cancers

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Hospitals, Health Technology, General Health, Biotechnology, CME, ACR, CT, Radiation, University, GE HealthCare, Internal medicine, Hepatocellular carcinoma, Liver disease, Neoplasm, Thomas Jefferson University, CEUS, Society, Agent handling, United States of Europe, University of California, San Diego Performance-Based Skills Assessment, Approximation error, MR, Brain, Kidney, Radiology, Black, AASLD, Google Images, Patient, Risk, Physician, Treatment, American Indians, Liver cancer, ICUS, University of Bologna, Diagnosis, European Association for the Study of the Liver, American College, FDA, White, HCC, UCAS, Medical imaging, Medical device, Liver, Biology, Medicine

New physician guidelines now recommend use of contrast-enhanced ultrasound (CEUS) to diagnose hepatocellular carcinoma (HCC), the most common primary liver cancer.

Key Points: 
  • New physician guidelines now recommend use of contrast-enhanced ultrasound (CEUS) to diagnose hepatocellular carcinoma (HCC), the most common primary liver cancer.
  • The new guidelines recommend CEUS for diagnosing HCC when MR and CT are inconclusive, unavailable or contraindicated.
  • CEUS uses FDA-approved “microbubble” ultrasound contrast agents (UCAs) that are administered intravenously during an ultrasound scan.
  • UCAs are manufactured and sold in the US and elsewhere by Bracco, Lantheus and GE Healthcare.

Hepatitis C: Britons getting tattoos and cosmetic procedures abroad may be at risk – here's how to avoid it

Retrieved on: 
Thursday, September 28, 2023
Amnesia, Infection, Prison, Risk, Hepatitis, Bleeding, HIV, Hepatocellular carcinoma, Liver disease, Myalgia, Decontamination, Fever, Cirrhosis, Brain, Needle, Diarrhea, Hepatitis C, Liver cancer, Vomiting, Bruise, Jaundice, Blood, Recreational drug use, Abdomen, Nausea, Liver, Infant, NHS, Chronic liver disease, Headache, Fatigue, Dentistry, Pharmaceutical industry, Vaccine, Medical device

A growing number of people living in the UK are going abroad to have tattoos, piercings and cosmetic surgeries.

Key Points: 
  • A growing number of people living in the UK are going abroad to have tattoos, piercings and cosmetic surgeries.
  • But people heading abroad for cosmetic procedures may want to be extra cautious – with recent reports suggesting thousands of UK residents may have unknowingly contracted hepatitis C this way.
  • Over 170 million people worldwide are estimated to have hepatitis C. There are approximately one million new infections each year.

What is hepatitis C?

    • In rare cases, hepatitis C can also be spread through sexual intercourse, or from an infected mother to an infant during childbirth.
    • But up to 85% of those infected develop chronic hepatitis – where the virus remains in the body.
    • Hepatitis C is still very treatable in chronic form, though treatments have better outcomes the sooner they’re received.
    • An estimated one in five people with chronic hepatitis C develop a severe liver cancer called hepatocellular carcinoma.

Risk from medical or cosmetic procedures

    • Improper sterilisation also carries risk of other diseases, such as HIV and hepatitis B.
    • Several studies have reported that tattoos done in non-professional settings, such as those received in prisons, carry an increased risk of contracting hepatitis C due to improper sterilisation.
    • Even tattoos done in professional tattoo parlours may carry an increased risk if reusable needles aren’t adequately sterilised between clients.
    • Although data is limited, this risk is probably the same for cosmetic and dental procedures.

How can you avoid it?

    • If in the UK, ask to see the business’s licence to ensure they’re registered with a local council.
    • With any injectable, ideally these should be done by a medical professional – such as a nurse or dentist.
    • If it comes back positive, get treated as soon as possible as hepatitis C virus is a highly treatable infection.

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

Retrieved on: 
Tuesday, September 26, 2023
DNA, PK, Francis Crick Institute, MYC, Methylation, Therapy, Hepatocellular carcinoma, Chills, Fever, Pharmacokinetics, Omega, King's College London, Part, Messenger, University College London Hospitals NHS Foundation Trust, PIN, Patient, Cancer, Webcast, DNA methylation, LNP, FDA, HCC, Safety, Vaccine, Pharmaceutical industry

CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced encouraging preliminary safety, tolerability, pharmacokinetic and translational data from the initial two dose level cohorts (n=8) from Part 1 of its ongoing Phase 1/2 MYCHELANGELO™ I study evaluating OTX-2002 in patients with hepatocellular carcinoma (HCC) and other solid tumors associated with the c-MYC (MYC) gene. OTX-2002, the Company’s lead development candidate, is designed to pre-transcriptionally downregulate MYC, a master oncogene implicated in more than 50% of all cancers and approximately 70% of HCC cases.

Key Points: 
  • “These early clinical data are consistent with our preclinical experiments, giving us confidence that our approach has the potential to translate to anti-tumor activity and clinical benefit.
  • These preliminary data cover the first two dose cohorts from the monotherapy dose escalation portion of the trial, which is currently being conducted at clinical sites across the United States and Asia.
  • These new data, while early, are incredibly promising and highlight the potential of programmable epigenomic mRNA therapeutics to provide a groundbreaking new strategy to pre-transcriptionally control gene regulation.
  • Omega will host a webcast and conference call for analysts and investors to review these data today, Tuesday, September 26, 2023, at 8:00 a.m.